Which has higher valuation and earnings, ANRO or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is ANRO or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Structure Therapeutics N/A -24.91% -23.67%

Is RLAY or ANRO more profitable?

Relay Therapeutics' return on equity of -43.94% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Alto Neuroscience N/A -47.22% -38.81%

Which has higher valuation & earnings, IRON or ANRO?

Disc Medicine is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is IRON or ANRO more profitable?

Disc Medicine's return on equity of -36.94% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Alto Neuroscience N/A -47.22% -38.81%

Which has better earnings and valuation, MLYS or ANRO?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is MLYS or ANRO more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Alto Neuroscience N/A -47.22% -38.81%

Alto Neuroscience (ANRO) Competitors

$18.25 -0.01 (-0.05%)

Closing price 03:59 PM Eastern

Extended Trading

$18.66 +0.40 (+2.21%)

As of 04:31 PM Eastern

Compare

ANRO vs. GPCR, RLAY, ARQT, IRON, and MLYS

Should you buy Alto Neuroscience stock or one of its competitors? MarketBeat compares Alto Neuroscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alto Neuroscience include Structure Therapeutics (GPCR), Relay Therapeutics (RLAY), Arcutis Biotherapeutics (ARQT), Disc Medicine (IRON), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

How does Alto Neuroscience compare to Structure Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Structure Therapeutics' return on equity of -24.91% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Structure Therapeutics	N/A	-24.91%	-23.67%

In the previous week, Structure Therapeutics had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Structure Therapeutics and 0 mentions for Alto Neuroscience. Structure Therapeutics' average media sentiment score of 0.41 beat Alto Neuroscience's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Structure Therapeutics	Neutral

Alto Neuroscience currently has a consensus target price of $35.25, indicating a potential upside of 93.14%. Structure Therapeutics has a consensus target price of $109.25, indicating a potential upside of 189.25%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Alto Neuroscience has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, suggesting that its share price is 235% less volatile than the broader market.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

91.8% of Structure Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Structure Therapeutics beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Relay Therapeutics currently has a consensus price target of $23.30, indicating a potential upside of 70.57%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 93.14%. Given Alto Neuroscience's higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Relay Therapeutics had 5 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Relay Therapeutics and 0 mentions for Alto Neuroscience. Relay Therapeutics' average media sentiment score of 0.13 beat Alto Neuroscience's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Alto Neuroscience	Neutral

Relay Therapeutics' return on equity of -43.94% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	170.50	-$276.48M	-$1.57	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Relay Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Alto Neuroscience (NYSE:ANRO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 0 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Alto Neuroscience's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Arcutis Biotherapeutics	Positive

Alto Neuroscience has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Alto Neuroscience currently has a consensus target price of $35.25, indicating a potential upside of 93.14%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 57.85%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Alto Neuroscience is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alto Neuroscience has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Disc Medicine is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Disc Medicine currently has a consensus price target of $105.30, indicating a potential upside of 60.03%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 93.14%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Disc Medicine had 8 more articles in the media than Alto Neuroscience. MarketBeat recorded 8 mentions for Disc Medicine and 0 mentions for Alto Neuroscience. Disc Medicine's average media sentiment score of 0.10 beat Alto Neuroscience's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Disc Medicine	Neutral
Alto Neuroscience	Neutral

Disc Medicine's return on equity of -36.94% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Alto Neuroscience	N/A	-47.22%	-38.81%

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Summary

Disc Medicine beats Alto Neuroscience on 7 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 9 mentions for Mineralys Therapeutics and 0 mentions for Alto Neuroscience. Mineralys Therapeutics' average media sentiment score of 0.51 beat Alto Neuroscience's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Mineralys Therapeutics	Positive
Alto Neuroscience	Neutral

Mineralys Therapeutics' return on equity of -27.92% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Alto Neuroscience	N/A	-47.22%	-38.81%

84.5% of Mineralys Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mineralys Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Mineralys Therapeutics presently has a consensus target price of $49.33, indicating a potential upside of 119.26%. Alto Neuroscience has a consensus target price of $35.25, indicating a potential upside of 93.14%. Given Mineralys Therapeutics' higher possible upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Mineralys Therapeutics beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$640.82M	$3.34B	$6.49B	$23.05B
Dividend Yield	N/A	2.30%	2.67%	4.10%
P/E Ratio	-7.54	18.61	23.92	30.30
Price / Sales	N/A	298.40	507.55	22.44
Price / Cash	N/A	51.45	26.99	18.46
Price / Book	3.75	8.04	10.28	4.61
Net Income	-$63.24M	$23.89M	$3.57B	$1.07B
7 Day Performance	-7.25%	-5.97%	-1.43%	-1.80%
1 Month Performance	-24.77%	2.78%	3.27%	-1.21%
1 Year Performance	610.16%	36.26%	23.37%	21.30%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	1.8409 of 5 stars	$18.25 0.0%	$35.25 +93.1%	+614.1%	$640.82M	N/A	N/A	N/A
GPCR Structure Therapeutics	2.8875 of 5 stars	$37.19 -3.5%	$109.25 +193.8%	+77.9%	$2.80B	N/A	N/A	136	News Coverage
RLAY Relay Therapeutics	2.5602 of 5 stars	$15.73 +10.3%	$23.30 +48.1%	+302.4%	$2.69B	$10.68M	N/A	330	Analyst Upgrade Gap Up
ARQT Arcutis Biotherapeutics	3.3686 of 5 stars	$20.80 -3.1%	$34.00 +63.4%	+47.7%	$2.69B	$415.62M	N/A	150
IRON Disc Medicine	1.9315 of 5 stars	$68.11 -5.4%	$105.30 +54.6%	+33.9%	$2.65B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. GPCR, RLAY, ARQT, IRON, and MLYS

How does Alto Neuroscience compare to Structure Therapeutics?

Summary

How does Alto Neuroscience compare to Relay Therapeutics?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

How does Alto Neuroscience compare to Disc Medicine?

Summary

How does Alto Neuroscience compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. GPCR, RLAY, ARQT, IRON, and MLYS

How does Alto Neuroscience compare to Structure Therapeutics?

Is ANRO or GPCR more profitable?

Does the media refer more to ANRO or GPCR?

Do analysts prefer ANRO or GPCR?

Which has more risk and volatility, ANRO or GPCR?

Which has higher valuation and earnings, ANRO or GPCR?

Do institutionals & insiders believe in ANRO or GPCR?

Summary

How does Alto Neuroscience compare to Relay Therapeutics?

Do institutionals and insiders hold more shares of RLAY or ANRO?

Which has more volatility and risk, RLAY or ANRO?

Do analysts prefer RLAY or ANRO?

Does the media favor RLAY or ANRO?

Is RLAY or ANRO more profitable?

Which has better earnings & valuation, RLAY or ANRO?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Does the media refer more to ANRO or ARQT?

Is ANRO or ARQT more profitable?

Do analysts recommend ANRO or ARQT?

Which has more volatility & risk, ANRO or ARQT?

Which has preferable valuation and earnings, ANRO or ARQT?

Summary

How does Alto Neuroscience compare to Disc Medicine?

Do insiders & institutionals believe in IRON or ANRO?

Which has higher valuation & earnings, IRON or ANRO?

Do analysts recommend IRON or ANRO?

Does the media favor IRON or ANRO?

Is IRON or ANRO more profitable?

Which has more risk & volatility, IRON or ANRO?

Summary

How does Alto Neuroscience compare to Mineralys Therapeutics?

Which has better earnings and valuation, MLYS or ANRO?

Does the media favor MLYS or ANRO?

Is MLYS or ANRO more profitable?

Do institutionals and insiders believe in MLYS or ANRO?

Which has more risk and volatility, MLYS or ANRO?

Do analysts rate MLYS or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools